tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Heart Failure D006333 36 associated lipids
Angioedema D000799 6 associated lipids
Fractures, Spontaneous D005598 4 associated lipids
Hydronephrosis D006869 4 associated lipids
Trypanosomiasis D014352 5 associated lipids
Alopecia D000505 14 associated lipids
Liver Diseases D008107 31 associated lipids
Corneal Diseases D003316 13 associated lipids
Testicular Diseases D013733 15 associated lipids
Facial Dermatoses D005148 7 associated lipids
Hypersensitivity D006967 22 associated lipids
Osteosarcoma D012516 50 associated lipids
Acne Vulgaris D000152 35 associated lipids
Urination Disorders D014555 9 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Anemia, Hemolytic D000743 4 associated lipids
Leukemia, Erythroblastic, Acute D004915 41 associated lipids
Vision Disorders D014786 10 associated lipids
Multiple Myeloma D009101 13 associated lipids
Osteochondrodysplasias D010009 3 associated lipids
Melanoma D008545 69 associated lipids
Hematologic Diseases D006402 3 associated lipids
Muscular Dystrophies D009136 10 associated lipids
Osteoporosis D010024 12 associated lipids
Anemia, Aplastic D000741 6 associated lipids
Kidney Diseases D007674 29 associated lipids
Hematuria D006417 13 associated lipids
Weight Gain D015430 101 associated lipids
Brain Diseases D001927 27 associated lipids
Cardiovascular Diseases D002318 24 associated lipids
Infection D007239 6 associated lipids
Abnormalities, Multiple D000015 13 associated lipids
Hypersensitivity, Delayed D006968 43 associated lipids
Glioma D005910 112 associated lipids
Cell Transformation, Neoplastic D002471 126 associated lipids
Bone Diseases D001847 4 associated lipids
Leukemia P388 D007941 43 associated lipids
Ulcer D014456 16 associated lipids
Hypercholesterolemia D006937 91 associated lipids
Obesity D009765 29 associated lipids
Thrombosis D013927 49 associated lipids
Bradycardia D001919 13 associated lipids
Hemorrhage D006470 15 associated lipids
Proteinuria D011507 30 associated lipids
Lymphoma D008223 18 associated lipids
Femur Head Necrosis D005271 5 associated lipids
Alzheimer Disease D000544 76 associated lipids
Drug Hypersensitivity D004342 20 associated lipids
Eye Diseases D005128 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Carcas-Sansuán AJ Limited sampling strategies for once daily tacrolimus exposure monitoring. 2016 Eur. J. Clin. Pharmacol. pmid:26939899
Vohra S et al. Clinical and serological efficacy of topical calcineurin inhibitors in oral lichen planus: a prospective randomized controlled trial. 2016 Int. J. Dermatol. pmid:26147635
Herz S et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. 2016 Eur. J. Cancer pmid:27614165
Hazama Y et al. Effect of Physiological Changes in the Skin on Systemic Absorption of Tacrolimus Following Topical Application in Rats. 2016 Biol. Pharm. Bull. pmid:26934927
Nakajima A et al. Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis. 2016 Mod Rheumatol pmid:26934454
Iguchi A et al. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation. 2016 Pediatr Transplant pmid:26526424
Pan GH et al. Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study. 2016 Oncotarget pmid:26933811
Moes DJ et al. Response: Limited sampling strategies for once daily tacrolimus exposure monitoring. 2016 Eur. J. Clin. Pharmacol. pmid:26931555
Doke T et al. Post-Transplant Membranous Nephropathy Associated with Chronic Active Antibody-Mediated Rejection and Hepatitis C Infection after Deceased Donor Renal Transplantation. 2016 Intern. Med. pmid:26875963
Fukuta T et al. Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity. 2016 Sci Rep pmid:27440054
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Lim SW et al. Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus. 2016 Sci Rep pmid:27436514
Knight SR Intrapatient variability in tacrolimus exposure - a useful tool for clinical practice? 2016 Transpl. Int. pmid:27283231
Shuker N et al. A high intrapatient variability in tacrolimus exposure is associated with poor long-term outcome of kidney transplantation. 2016 Transpl. Int. pmid:27188932
Rodrigues-Diez R et al. Calcineurin inhibitors cyclosporine A and tacrolimus induce vascular inflammation and endothelial activation through TLR4 signaling. 2016 Sci Rep pmid:27295076
Wen X et al. Comparison of Utilization and Clinical Outcomes for Belatacept- and Tacrolimus-Based Immunosuppression in Renal Transplant Recipients. 2016 Am. J. Transplant. pmid:27137884
Kolb M et al. Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. 2016 Biol. Blood Marrow Transplant. pmid:26880117
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Nie F et al. [Post-transplant kidney from C-III donation after cardiac death of children: a clinicopathologic study of 20 cases]. 2016 Zhonghua Bing Li Xue Za Zhi pmid:26879429
Song JL et al. Minimizing tacrolimus decreases the risk of new-onset diabetes mellitus after liver transplantation. 2016 World J. Gastroenterol. pmid:26877618
Viesselmann CW et al. Clinically Significant Drug Interaction Between Clotrimazole and Tacrolimus in Pancreas Transplant Recipients and Associated Risk of Allograft Rejection. 2016 Pharmacotherapy pmid:26877191
Than NN et al. Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. 2016 Scand. J. Gastroenterol. pmid:26458216
Žilinská Z et al. Impact of Trough Levels of Tacrolimus on Kidney Function and Graft Survival in Short and Longer Periods After Renal Transplantation. 2016 Transplant. Proc. pmid:27788794
Dharnidharka VR et al. Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. 2016 Transpl. Int. pmid:27564782
Wang X et al. Ureaplasma urealyticum Causes Hyperammonemia in an Experimental Immunocompromised Murine Model. 2016 PLoS ONE pmid:27537683
Rostaing L et al. Successful Transplantation in ABO- and HLA-Incompatible Living Kidney Transplant Patients: A Report on 12 Cases. 2016 Ther Apher Dial pmid:27073167
Malik N et al. A simple office-based procedure for patients with extensive vitiligo. 2016 J. Am. Acad. Dermatol. pmid:27745651
Lee JH et al. Stability of tacrolimus solutions in polyolefin containers. 2016 Am J Health Syst Pharm pmid:26796907
Cruzado JM et al. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation. 2016 Transpl. Int. pmid:27648523
Torrisi JS et al. Inhibition of Inflammation and iNOS Improves Lymphatic Function in Obesity. 2016 Sci Rep pmid:26796537
Chatterjee S and Agrawal D Tacrolimus in Corticosteroid-Refractory Vernal Keratoconjunctivitis. 2016 Cornea pmid:27310883
Yan L et al. Donor ABCB1 3435 C>T genetic polymorphisms influence early renal function in kidney transplant recipients treated with tacrolimus. 2016 Pharmacogenomics pmid:26784512
Wu YJ et al. Safe One-to-One Dosage Conversion From Twice-Daily to Once-Daily Tacrolimus in Long-Term Stable Recipients After Liver Transplantation. 2016 Ann. Transplant. pmid:26782179
Ward I et al. Digital Pulp Ulcerations and Inverse Gottron Papules in Melanoma Differentiation-Associated Gene 5-Related Dermatomyositis. 2016 J Clin Rheumatol pmid:27464773
EriÅŸ E et al. Evaluation of Effect of Topical Tacrolimus Treatment on Herpetic Stromal Keratitis in a Rat Model. 2016 Eye Contact Lens pmid:25996419
First MR et al. Use of low-dose tacrolimus and associated hypomagnesemia in the prevention of erectile dysfunction following prostatectomy for prostate cancer. 2016 Pharmacol Rep pmid:27607363
Pereira M et al. Hyperacute Rejection in a Kidney Transplant With Negative Crossmatch: A Case Report. 2016 Transplant. Proc. pmid:27742303
Nekkanti V et al. Design, Characterization, and In Vivo Pharmacokinetics of Tacrolimus Proliposomes. 2016 AAPS PharmSciTech pmid:26729532
Armand P et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. 2016 Br. J. Haematol. pmid:26729448
Badr R et al. Assessment of global ischemic/reperfusion and Tacrolimus administration on CA1 region of hippocampus: gene expression profiles of BAX and BCL2 genes. 2016 Bratisl Lek Listy pmid:27546370
Hanaoka K et al. A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy. 2016 Transpl. Immunol. pmid:27545900
Matsa E et al. Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. 2016 Cell Stem Cell pmid:27545504
Lee B et al. Appropriate timing of tacrolimus concentration measurements in the emergency department. 2016 Am J Health Syst Pharm pmid:27543574
Thao le Q et al. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. 2016 Int J Pharm pmid:26657273
Mokuda S and Oiwa H Successful treatment of FKBP51-expressed multicentric reticulohistiocytosis using combination therapy with low-dose denosumab and tacrolimus. 2016 Scand. J. Rheumatol. pmid:26652057
Komaki Y et al. Efficacy and Safety of Tacrolimus Therapy for Active Ulcerative Colitis; A Systematic Review and Meta-analysis. 2016 J Crohns Colitis pmid:26645641
Jung HJ et al. Improved oral absorption of tacrolimus by a solid dispersion with hypromellose and sodium lauryl sulfate. 2016 Int. J. Biol. Macromol. pmid:26642839
Imai Y et al. Histone deacetylase inhibitor panobinostat induces calcineurin degradation in multiple myeloma. 2016 JCI Insight pmid:27699258
Vadcharavivad S et al. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. 2016 J Clin Pharm Ther pmid:27191538
Elshatory YM et al. Diagnostic and Therapeutic Challenges. 2016 Retina (Philadelphia, Pa.) pmid:26225484
Thevissen K How promising are combinatorial drug strategies in combating Candida albicans biofilms? 2016 Future Med Chem pmid:27463947
Li X and Sun S Targeting the fungal calcium-calcineurin signaling network in overcoming drug resistance. 2016 Future Med Chem pmid:27463738
Ikeya K et al. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. 2016 J Crohns Colitis pmid:26581895
Gala-Lopez BL et al. Antiaging Glycopeptide Protects Human Islets Against Tacrolimus-Related Injury and Facilitates Engraftment in Mice. 2016 Diabetes pmid:26581595
Milgrom SA et al. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. 2016 J Med Case Rep pmid:27465468
Jung H et al. FK506 regulates pigmentation by maturing the melanosome and facilitating their transfer to keratinocytes. 2016 Pigment Cell Melanoma Res pmid:26581186
Pouché L et al. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. 2016 Pharmacogenomics pmid:26799749
Wu SY et al. Comprehensive risk assessment for early neurologic complications after liver transplantation. 2016 World J. Gastroenterol. pmid:27350733
Constantinescu AA et al. Differential influence of tacrolimus and sirolimus on mitochondrial-dependent signaling for apoptosis in pancreatic cells. 2016 Mol. Cell. Biochem. pmid:27344165
Shao K et al. Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation. 2016 Scand. J. Immunol. pmid:26524694
Cena T et al. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients. 2016 Transpl. Int. pmid:27343849
Moes DJ et al. Population pharmacokinetics and pharmacogenetics of once daily tacrolimus formulation in stable liver transplant recipients. 2016 Eur. J. Clin. Pharmacol. pmid:26521259
Yeo L and Ormerod AD Oral tacrolimus: a treatment option for recalcitrant erosive lichen planus. 2016 Clin. Exp. Dermatol. pmid:27339859
Hashimoto K et al. Pure red cell aplasia induced by anti-erythropoietin antibodies, well-controlled with tacrolimus. 2016 Int. J. Hematol. pmid:27338269
Binkhathlan Z et al. Reutilization of Tacrolimus Extracted from Expired Prograf® Capsules: Physical, Chemical, and Pharmacological Assessment. 2016 AAPS PharmSciTech pmid:26729529
Gardiner KM et al. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. 2016 Ann. Transplant. pmid:26729299
Chacon A and Mercer J Successful management of angiolymphoid hyperplasia with eosinophilia in a split-face trial of topical tacrolimus and timolol solution. 2016 G Ital Dermatol Venereol pmid:25014586
Grześk E et al. Cyclosporine-A, but not tacrolimus significantly increases reactivity of vascular smooth muscle cells. 2016 Pharmacol Rep pmid:26721374
McShane AJ et al. Therapeutic drug monitoring of immunosuppressants by liquid chromatography-mass spectrometry. 2016 Clin. Chim. Acta pmid:26721314
Riegersperger M et al. The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients. 2016 Clin. Lab. pmid:28164520
Pizzo HP et al. Sirolimus and tacrolimus coefficient of variation is associated with rejection, donor-specific antibodies, and nonadherence. 2016 Pediatr. Nephrol. pmid:27286686
Fernández de Castillo Torras L et al. Treatment with ulipristal acetate (Esmya(®)) and plasma levels of tacrolimus: a case report. 2016 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:27282803
Levitsky J et al. Immunoregulatory Effects of Everolimus on In Vitro Alloimmune Responses. 2016 PLoS ONE pmid:27275747
Schneider L et al. Study of the Atopic March: Development of Atopic Comorbidities. 2016 Pediatr Dermatol pmid:27273433
Kostereva NV et al. IGF-1 and Chondroitinase ABC Augment Nerve Regeneration after Vascularized Composite Limb Allotransplantation. 2016 PLoS ONE pmid:27272754
Raja R et al. A prospective study of collapsing focal segmental glomerulosclerosis. 2016 Ren Fail pmid:27266801
Sasaki T et al. Characteristic features of tacrolimus-induced lung disease in rheumatoid arthritis patients. 2016 Clin. Rheumatol. pmid:25644583
Serrano-Mollar A et al. Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis. 2016 Chest pmid:27020420
Seok J et al. Recalcitrant steroid-induced rosacea successfully treated with 0.03% tacrolimus and 595-nm pulsed dye laser. 2016 Eur J Dermatol pmid:27193042
Sisti A et al. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. 2016 An Bras Dermatol pmid:27192518
Ramachandran R et al. Cyclical cyclophosphamide and steroids is effective in resistant or relapsing nephrotic syndrome due to M-type phospholipase A2 receptor-related membranous nephropathy after tacrolimus therapy. 2016 Kidney Int. pmid:27181781
Bican Demir A et al. Two Cases With Developing Neurologic Complications After Liver Transplant. 2016 Exp Clin Transplant pmid:26643318
Al-Maawali AK et al. Modern Treatments and Stem Cell Therapies for Perianal Crohn's Fistulas. 2016 Can J Gastroenterol Hepatol pmid:28053967
Reiner J et al. After Intestinal Transplantation Kidney Function Is Impaired by Downregulation of Epithelial Ion Transporters in the Ileum. 2016 Transplant. Proc. pmid:27109987
Rao B et al. Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 2016 Transplant. Proc. pmid:27109983
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Baraldo M Meltdose Tacrolimus Pharmacokinetics. 2016 Transplant. Proc. pmid:27109969
Pretagostini R et al. Delayed Introduction of Everolimus in De Novo Renal Transplanted Patients: A Single-Center Experience. 2016 Transplant. Proc. pmid:27109947
Park OJ et al. A combination of excimer laser treatment and topical tacrolimus is more effective in treating vitiligo than either therapy alone for the initial 6 months, but not thereafter. 2016 Clin. Exp. Dermatol. pmid:26299799
Gomes RM et al. Ten-year kidney transplant survival of cyclosporine- or tacrolimus-treated patients in Brazil. 2016 Expert Rev Clin Pharmacol pmid:27181131
Felix MJ et al. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens. 2016 Pharmacotherapy pmid:26799522
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Shimizu K et al. Specific delivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its antiallergic effect. 2016 J Drug Target pmid:27030163
Vanhove T et al. High Intrapatient Variability of Tacrolimus Concentrations Predicts Accelerated Progression of Chronic Histologic Lesions in Renal Recipients. 2016 Am. J. Transplant. pmid:27013142
Kanazawa H et al. Chemotherapy-induced B-cell depletion in hepatoblastoma patients undergoing ABO-incompatible living donor liver transplantation. 2016 Pediatr Transplant pmid:27012966
Shipley CA and Spivakovsky S Tacrolimus or clobetasol for treatment of oral lichen planus. 2016 Evid Based Dent pmid:27012570
Ko DH et al. Performance Evaluation of a Restored Dimension TACR Assay: An Automated Platform for Measuring the Whole Blood Tacrolimus Concentration. 2016 Clin. Lab. pmid:27012028
Ha DH et al. Potential differentiation ability of gingiva originated human mesenchymal stem cell in the presence of tacrolimus. 2016 Sci Rep pmid:27721434
Taşoğlu Ö et al. Pregabalin: A New Adjunct in Calcineurin Inhibitor Pain Syndrome Treatment. 2016 Prog Transplant pmid:27312682
Tron C et al. A high performance liquid chromatography tandem mass spectrometry for the quantification of tacrolimus in human bile in liver transplant recipients. 2016 J Chromatogr A pmid:27837999